Your session is about to expire
← Back to Search
Other
AOC 1020 for Facioscapulohumeral Muscular Dystrophy (FORTITUDE-OLE Trial)
Phase 2
Waitlist Available
Research Sponsored by Avidity Biosciences, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Must not have
Unwilling or unable to comply with contraceptive requirements for the length of AOC 1020-CS2
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
"This trial will study the long-term effects of AOC 1020 given through an IV to adults with Facioscapulohumeral Muscular Dystrophy (FSHD)."
Who is the study for?
This trial is for adults with Facioscapulohumeral Muscular Dystrophy (FSHD), a type of muscular dystrophy that affects the muscles of the face, shoulder blades, and upper arms. Participants should have completed prior studies with AOC 1020 or meet specific health criteria.
What is being tested?
The study tests long-term safety and effectiveness of AOC 1020 when given through an IV. It's an open-label extension, meaning everyone knows they're getting AOC 1020 and there's no placebo group.
What are the potential side effects?
Possible side effects are not detailed here but typically include reactions at the infusion site, muscle pain or weakness, fatigue, and potential allergic responses to the medication.
Eligibility Criteria
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I cannot or will not follow the birth control rules during the AOC 1020-CS2 study.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: AOC 1020 RegimenExperimental Treatment1 Intervention
AOC 1020 Dose Regimen; Nine doses administered intravenously over 24 months. Treatment assignment will be based on treatment received in AOC 1020-CS1.
Find a Location
Who is running the clinical trial?
Avidity Biosciences, Inc.Lead Sponsor
7 Previous Clinical Trials
874 Total Patients Enrolled
Amy Halseth, Ph.D.Study DirectorAvidity Biosciences, Inc.